Post-Operative Pain (Central Nervous System) - Drugs in Development, 2021
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Operative Pain - Drugs in Development, 2021, provides an overview of the Post-Operative Pain (Central Nervous System) pipeline landscape.
Pain is one of the main postoperative adverse outcomes causing distress to patients. Degree of postoperative pain experienced by individuals varies. Cause of pain includes peripheral nerve damage during surgery, inflammation at the site of the wound and damage to bodily tissues during surgery. Risk factors include site of the operation, age, level of fear or anxiety, surgical procedure, personal preference and response to agents given. Treatment for post-operative pain includes analgesia and anesthetics.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Operative Pain - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Post-Operative Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Post-Operative Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 2, 8, 27, 19, 6, 31, 1 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Unknown stages comprises 1, 3 and 1 molecules, respectively.
Post-Operative Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Operative Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Post-Operative Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post-Operative Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post-Operative Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post-Operative Pain (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post-Operative Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post-Operative Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Post-Operative Pain (Central Nervous System) - Drugs in Development, 2021
Table of Contents
Introduction
Post-Operative Pain - Overview
Post-Operative Pain - Therapeutics Development
Post-Operative Pain - Therapeutics Assessment
Post-Operative Pain - Companies Involved in Therapeutics Development
Post-Operative Pain - Drug Profiles
Post-Operative Pain - Dormant Projects
Post-Operative Pain - Discontinued Products
Post-Operative Pain - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Post-Operative Pain, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Companies, 2021 (Contd..2)
Number of Products under Development by Companies, 2021 (Contd..3)
Number of Products under Development by Companies, 2021 (Contd..4)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Products under Development by Companies, 2021 (Contd..5)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Target, 2021 (Contd..1)
Number of Products by Stage and Target, 2021 (Contd..2)
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2021 (Contd..2)
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Post-Operative Pain - Pipeline by Acadia Pharmaceuticals Inc, 2021
Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals Inc, 2021
Post-Operative Pain - Pipeline by Adare Pharma Solutions, 2021
Post-Operative Pain - Pipeline by Adynxx Inc, 2021
Post-Operative Pain - Pipeline by Algomedix Inc, 2021
Post-Operative Pain - Pipeline by Altus Formulation Inc, 2021
Post-Operative Pain - Pipeline by AmacaThera Inc, 2021
Post-Operative Pain - Pipeline by Andros Pharmaceuticals Co Ltd, 2021
Post-Operative Pain - Pipeline by AngioChem Inc, 2021
Post-Operative Pain - Pipeline by Antibe Therapeutics Inc, 2021
Post-Operative Pain - Pipeline by Bayer AG, 2021
Post-Operative Pain - Pipeline by Beijing Join Chain Medicine Co Ltd, 2021
Post-Operative Pain - Pipeline by Benuvia Therapeutics Inc, 2021
Post-Operative Pain - Pipeline by Brainfarma Chemical and Pharmaceutical Industry Ltda, 2021
Post-Operative Pain - Pipeline by Cali Pharmaceuticals LLC, 2021
Post-Operative Pain - Pipeline by Camurus AB, 2021
Post-Operative Pain - Pipeline by Cara Therapeutics Inc, 2021
Post-Operative Pain - Pipeline by Cellix Bio Pvt Ltd, 2021
Post-Operative Pain - Pipeline by Chromocell Corp, 2021
Post-Operative Pain - Pipeline by Clexio Biosciences Ltd, 2021
Post-Operative Pain - Pipeline by Concentric Analgesics Inc, 2021
Post-Operative Pain - Pipeline by Cytogel Pharma LLC, 2021
Post-Operative Pain - Pipeline by Dompe Farmaceutici SpA, 2021
Post-Operative Pain - Pipeline by Douleur Therapeutics Inc, 2021
Post-Operative Pain - Pipeline by Esteve Pharmaceuticals SA, 2021
Post-Operative Pain - Pipeline by Euclises Pharmaceuticals Inc, 2021
Post-Operative Pain - Pipeline by Eupraxia Pharmaceuticals Inc, 2021
Post-Operative Pain - Pipeline by Flexion Therapeutics Inc, 2021
Post-Operative Pain - Pipeline by Fujimoto Pharmaceutical Corp, 2021
Post-Operative Pain - Pipeline by Grunenthal GmbH, 2021
Post-Operative Pain - Pipeline by Guangdong Jiabo Pharmaceutical Co Ltd, 2021
Post-Operative Pain - Pipeline by H. Lundbeck AS, 2021
Post-Operative Pain - Pipeline by Hana Pharm Co Ltd, 2021
Post-Operative Pain - Pipeline by Hefei Cosource Pharmaceutical Inc, 2021
Post-Operative Pain - Pipeline by Heron Therapeutics Inc, 2021
Post-Operative Pain - Pipeline by IACTA Pharmaceuticals Inc, 2021
Post-Operative Pain - Pipeline by InSitu Biologics LLC, 2021
Post-Operative Pain - Pipeline by Insys Therapeutics Inc (Inactive)
Post-Operative Pain - Pipeline by InterK Peptide Therapeutics Ltd, 2021
Post-Operative Pain - Pipeline by Ionis Pharmaceuticals Inc, 2021
Post-Operative Pain - Pipeline by iX Biopharma Ltd, 2021
Post-Operative Pain - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
Post-Operative Pain - Pipeline by Jiangsu Huatai Chenguang Pharmaceutical Co Ltd, 2021
Post-Operative Pain - Pipeline by Liquidia Technologies Inc, 2021
Post-Operative Pain - Pipeline by Lumosa Therapeutics Co Ltd, 2021
Post-Operative Pain - Pipeline by Luye Pharma Group Ltd, 2021
Post-Operative Pain - Pipeline by Medical Developments International Ltd, 2021
Post-Operative Pain - Pipeline by MedinCell SA, 2021
Post-Operative Pain - Pipeline by Mundipharma International Ltd, 2021
Post-Operative Pain - Pipeline by Nang Kuang Pharmaceutical Co Ltd, 2021
Post-Operative Pain - Pipeline by Neokera LLC, 2021
Post-Operative Pain - Pipeline by Neumentum Inc, 2021
Post-Operative Pain - Pipeline by NeurAxon Pharma Inc, 2021
Post-Operative Pain - Pipeline by NeuroPn Therapeutics LLC, 2021
Post-Operative Pain - Pipeline by Nevakar Inc, 2021
Post-Operative Pain - Pipeline by Ocular Therapeutix Inc, 2021
Post-Operative Pain - Pipeline by Pacira BioSciences Inc, 2021
Post-Operative Pain - Pipeline by PainReform Ltd, 2021
Post-Operative Pain - Pipeline by Pharmazz Inc, 2021
Post-Operative Pain - Pipeline by PhytoHealth Corp, 2021
Post-Operative Pain - Pipeline by PolyPid Ltd, 2021
Post-Operative Pain - Pipeline by Quoin Pharmaceuticals Ltd, 2021
Post-Operative Pain - Pipeline by Revogenex Inc, 2021
Post-Operative Pain - Pipeline by RHNanopharmacuticals LLC, 2021
Post-Operative Pain - Pipeline by Rottapharm Biotech Srl, 2021
Post-Operative Pain - Pipeline by Sedor Pharmaceuticals LLC, 2021
Post-Operative Pain - Pipeline by Seelos Therapeutics, Inc., 2021
Post-Operative Pain - Pipeline by Serina Therapeutics Inc, 2021
Post-Operative Pain - Pipeline by Shijiazhuang Yiling Pharmaceutical Co Ltd, 2021
Post-Operative Pain - Pipeline by Sichuan Haisco Pharmaceutical Co Ltd, 2021
Post-Operative Pain - Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2021
Post-Operative Pain - Pipeline by SiteOne Therapeutics Inc, 2021
Post-Operative Pain - Pipeline by Sotex Pharm Firm, 2021
Post-Operative Pain - Pipeline by Stragen New Molecules, 2021
Post-Operative Pain - Pipeline by Taiwan Liposome Co Ltd, 2021
Post-Operative Pain - Pipeline by Teikoku Pharma USA Inc, 2021
Post-Operative Pain - Pipeline by Theracaine LLC, 2021
Post-Operative Pain - Pipeline by Trevena Inc, 2021
Post-Operative Pain - Pipeline by Vertex Pharmaceuticals Inc, 2021
Post-Operative Pain - Pipeline by Viatris Inc, 2021
Post-Operative Pain - Pipeline by Virpax Pharmaceuticals Inc, 2021
Post-Operative Pain - Pipeline by Vivozon Inc, 2021
Post-Operative Pain - Pipeline by Xgene Pharmaceutical Inc, 2021
Post-Operative Pain - Pipeline by Xigen SA, 2021
Post-Operative Pain - Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, 2021
Post-Operative Pain - Dormant Projects, 2021
Post-Operative Pain - Dormant Projects, 2021 (Contd..1)
Post-Operative Pain - Dormant Projects, 2021 (Contd..2)
Post-Operative Pain - Dormant Projects, 2021 (Contd..3)
Post-Operative Pain - Dormant Projects, 2021 (Contd..4)
Post-Operative Pain - Discontinued Products, 2021
List of Figures
Number of Products under Development for Post-Operative Pain, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021
Global CNS Therapeutics Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 03-Oct-2023 Price: US 3380 Onwards Pages: 101
Market Overview of Global CNS Therapeutics market:
According to our latest research, the global CNS Therapeutics market looks promising in the next 5 years. As of 2022, the global CNS Therapeutics market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
Central nervous system (CNS) disease is a widespread condition in which the brain does not function properly, limiting health and function. The......
Global CNS Therapeutics Market Insights, Forecast to 2029
Published: 11-Aug-2023 Price: US 4900 Onwards Pages: 117
Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson's disease, dystonia, and essential tremor are central nervous system conditions. What they ha......
Central Nervous System Disorders Therapeutics Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application
Published: 18-Apr-2023 Price: US 3500 Onwards Pages: 131
This report describes the global market size of Central Nervous System Disorders Therapeutics from 2018 to 2022 and its CAGR from 2018 to 2022, and also forecasts its market size to the end of 2028 and its CAGR from 2023 to 2028.
For geography segment, regional supply, demand, major players, price is presented from 2018 to 2028. This report cover following regions:
North America
South America
Asia & Pacific
Europe
MEA
The key countries for ......
Global CNS Therapeutics Market Insights: Impact of COVID-19 and Future Expectations to 2028
Published: 16-Mar-2023 Price: US 3260 Onwards Pages: 117
Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson's disease, dystonia, and essential tremor are central nervous system conditions. What they ha......
Global CNS Therapeutics Market Research Report 2023
Published: 06-Feb-2023 Price: US 2900 Onwards Pages: 103
Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson's disease, dystonia, and essential tremor are central nervous system conditions. What they ha......
CNS Therapeutics Market, Global Outlook and Forecast 2023-2029
Published: 03-Feb-2023 Price: US 3250 Onwards Pages: 100
Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson's disease, dystonia, and essential tremor are central nervous system conditions. What they ha......
Global Central Nervous System Disorders Therapeutics Market Growth (Status and Outlook) 2023-2029
Published: 02-Feb-2023 Price: US 3660 Onwards Pages: 88
Central Nervous System (CNS) disorders are also called as neurological and psychiatric disorders. CNS disorders can affect either the brain or spinal cord, or both.
LPI (LP Information)' newest research report, the "Central Nervous System Disorders Therapeutics Industry Forecast" looks at past sales and reviews total world Central Nervous System Disorders Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Central Nervous System Disorder......
Global Central Nervous System Disorders Therapeutics Market Research Report 2023
Published: 31-Jan-2023 Price: US 2900 Onwards Pages: 84
Central Nervous System (CNS) disorders are also called as neurological and psychiatric disorders. CNS disorders can affect either the brain or spinal cord, or both.
Highlights
The global Central Nervous System Disorders Therapeutics market was valued at US$ 134580 million in 2022 and is anticipated to reach US$ 169200 million by 2029, witnessing a CAGR of 3.9% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating......
Central Nervous System Disorders Therapeutics Market, Global Outlook and Forecast 2023-2029
Published: 31-Jan-2023 Price: US 3250 Onwards Pages: 69
Central Nervous System (CNS) disorders are also called as neurological and psychiatric disorders. CNS disorders can affect either the brain or spinal cord, or both.
This report aims to provide a comprehensive presentation of the global market for Central Nervous System Disorders Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and ma......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
